TACSTD2 and carcinoma: After initial statistical subgrouping using the Cutoff Finder [33], we decided to group all carcinomas with any significant TROP2 expression (IRS ≥ 2) as TROP2 positive, as we detected no statistical differences regarding patient survival between the different TROP2 expression grades in our initial univariable survival analyses.